Funding: GSK (212620) Disclosures: Gideon Hirschfield: Intercept: Consultant, GSK: Consultant, CymaBay: Consultant, Ipsen: Consultant, Falk: Consultant, Pliant: Consultant, Morphogen: Consultant, Roche: Consultant, Mirum: Consultant, Advanz: Consultant, Chemomab: Consultant, Gilead: Consultant, Kowa: Consultant, Christopher Bowlus: Calliditas: Grant/Research Support, ChemoMab: Grant/Research Support, ChemoMab: Consultant, COUR Phamaceuticals: Grant/Research Support, Cymabay: Grant/Research Support, Cymabay: Consultant, Cymabay: Consultant, Gilead: Grant/Research Support, GSK Pharmaceuticals: Grant/Research Support, GSK Pharmaceuticals: Consultant, Hanmi: Grant/Research Support, Intercept: Grant/Research Support, Invea Therapeutics: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, NGM Bio: Consultant, Novartis: Grant/Research Support, Novo Nordisk: Grant/Research Support, Pliant Therapeutics: Grant/Research Support, Pliant Therapeutics: Consultant, Viking Therapeutics: Grant/Research Support, Zydus Therapeutics: Grant/Research Support, David Jones: Nothing to Disclose, Andreas Kremer: Abbvie: Advisor, Advanz: Advisor, Alentis: Advisor, AlphaSigma: Speaking and Teaching, AstraZeneca: Advisor, Avior: Advisor, Bayer: Advisor, CymaBay: Advisor, Escient: Advisor, Falk: Speaker, Falk: Speaker, Gilead: Advisor, GSK: Advisor, Intercept: Advisor, Ipsen: Speaking and Teaching, Ipsen: Speaking and Teaching, Mirum: Advisor, Mirum: Advisor, MSD: Advisor, Myr: Advisor, Roche: Advisor, Takeda: Advisor, Viofor: Advisor, Marlyn Mayo: CymaBay: Grant/Research Support, CymaBay: Consultant, GSK: Grant/Research Support, GSK: Consultant, Intercept: Grant/Research Support, IntraSana: Consultant, Ipsen: Grant/Research Support, Ipsen: Consultant, Mallinckrodt: Grant/Research Support, Mallinckrodt: Consultant, Mirum: Grant/Research Support, Target RWE: Grant/Research Support, Atsushi Tanaka: Nothing to Disclose, Pietro Andreone: Nothing to Disclose, Jidong Jia: Nothing to Disclose, Qinglong Jin: Nothing to Disclose, Ricardo Macas-Rodrguez: Nothing to Disclose, Alexander Cobitz: Nothing to Disclose, Brooke Currie: GSK: Employee, GSK: Stock - publicly traded company, Ciara Gorey: Nothing to Disclose, Eunhye Kang: Nothing to Disclose, Ivana Lazic: GSK: Employee, Danielle Podmore: Nothing to Disclose, Andrea Ribeiro: Nothing to Disclose, Jennifer Shannon: Nothing to Disclose, Brandon Swift: GSK: Employee, Philip Troke: Nothing to Disclose, Megan McLaughlin: Nothing to Disclose, Cynthia Levy: Cymabay: Grant/Research Support, Cymabay: Consultant, Intercept: Grant/Research Support, Intercept: Consultant, Calliditas: Grant/Research Support, Calliditas: Consultant, GSK: Consultant, GSK: Grant/Research Support, Ipsen: Grant/Research Support, Ipsen: Consultant, Mirum: Grant/Research Support, Mirum: Consultant, Zydus: Grant/Research Support, Gilead: Grant/Research Support, Gilead: Consultant, Escient: Grant/Research Support, Kowa: Grant/Research Support, Kowa: Consultant, Genfit: Grant/Research Support, COur: Advisor, Chemomab: Consultant 2362 PERIDUCTAL IRON-CORRECTED T 1 IS A PREDICTOR OF ADVERSE OUTCOMES IN LARGE-DUCT PRIMARY SCLEROSING CHOLANGITIS Emmanuel Selvaraj 1 Bruno Paun 2 Cayden Beyer 2 Amy Herlihy 2 Michael Brady 2 Emma Culver 1 Adam Bailey 1 Michael Pavlides 3 , 1 University of Oxford, 2 Perspectum Ltd, 3 Oxford University Background: Concentric periductal fibrosis, commonly referred to as onion skin fibrosis, is a histological hallmark of primary sclerosing cholangitis (PSC)
Clinical Takeaway Seronegative Lyme disease remains controversial and difficult to study
Su poder antioxidante, desintoxicante y regenerador es esencial para la salud y la longevidad, participando activamente en la eliminacin de los radicales libres en el organismo
Dong Y, Yang M, Zhang J, Peng X, Cheng J, Cui T, Du J
